Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session

Gainers

• Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.
• Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) shares jumped 140% to $0.6041 after the company entered into a definitive merger agreement with GRI Bio.
• Panbela Therapeutics, Inc. (NASDAQ:PBLA) gained 52% to $0.2175. Panbela received EMA opinion on orphan designation for Ivospemin in combination with Gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
• Immix Biopharma, Inc. (NASDAQ:IMMX) jumped 46% to $2.1695 after the company announced it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 with 85% ORR and 71% CR/sCR at the therapeutic dose from the first 20 patients in an ongoing phase 1b relapsed/refractory multiple myeloma ongoing clinical trial.
• Senti Biosciences, Inc. (NASDAQ:SNTI) rose 45% to $2.09 after dipping more than 21% on Tuesday.
• Avidity Biosciences, Inc. (NASDAQ:RNA) shares climbed 44.3% to $15.84 after the company announced AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever successful targeted delivery of RNA into muscle.
• BIMI International Medical, Inc. (NASDAQ:BIMI) gained 28.1% to $2.6649. BIMI reported entry into a material definitive agreement for the acquisition of Wuzhou Qiangsheng Hospital Co., Ltd., Suzhou Eurasia Hospital Co., Ltd. and Yunan Yuxi Minkang Hospital Co., Ltd.
• Wave Life Sciences Ltd. (NASDAQ:WVE) gained 21.1% to $5.80. SVB Leerink maintained WAVE Life Sciences with a Market Perform and raised the price target from $2 to $7.
• Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares gained 21.4% to $31.38 after the company announced results from the Phase 1 clinical trial evaluating KT-474 in patients with HS and AD and Sanofi's decision to advance KT-474 into Phase 2 clinical trials.
• Aspen Group, Inc. (NASDAQ:ASPU) gained 17.4% to $0.41 after reporting strong quarterly sales.
• REV Group, Inc. (NYSE:REVG) jumped 17.2% to $15.57 as the company reported a fourth-quarter FY22 sales growth of 5.7% year-over-year to $623.6 million, beating the consensus of $595 million.
• Nuvve Holding Corp. (NASDAQ:NVVE) gained 16.9% to $0.7477.
• Meiwu Technology Company Limited (NASDAQ:WNW) jumped 16.3% to $2.14.
• United Insurance Holdings Corp. (NASDAQ:UIHC) jumped 16.2% to $0.5578.
• Dyne Therapeutics, Inc. (NYSE:DYN) jumped 14.7% to $14.00.
• Sio Gene Therapies Inc. (NASDAQ:SIOX) gained 14.7% to $0.3537.
• Otonomy, Inc. (NASDAQ:OTIC) jumped 14.4% to $0.1399.
• Harmonic Inc. (NASDAQ:HLIT) gained 12.9% to $14.86
• Happiness Development Group Limited (NASDAQ:HAPP) rose 12.9% to $3.9973after surging over 10% on Tuesday.
• Carvana Co. (NYSE:CVNA) gained 12.8% to $5.45.
• Appreciate Holdings, Inc. (NASDAQ:SFR) jumped 12.4% to $1.90.
• Harrow Health, Inc. (NASDAQ:HROW) surged 11.9% to $12.43. Harrow Health entered a binding agreement to acquire the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from Novartis.
• Mullen Automotive, Inc. (NASDAQ:MULN) jumped 10% to $0.2354. Mullen Automotive partnered with Loop Global to deploy EV charging solutions, including public DC fast charging network and residential offerings.
• QualTek Services Inc. (NASDAQ:QTEK) gained 9.3% to $0.5463.
• Cytokinetics, Incorporated (NASDAQ:CYTK) jumped 7.6% to $41.27. The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 8-3 against the approval of Cytokinetics heart failure drug, omecamtiv mecarbil.
• Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) gained 6.3% to $2.02. Processa Pharmaceuticals said PCS12852 successfully improves the clinical symptoms associated with gastroparesis in Phase 2A trial.

Losers

• Drive Shack Inc. (NYSE:DS) fell 55.3% to $0.2126. The company announced its intention to voluntarily delist from the NYSE and to deregister its common stock.
• ZyVersa Therapeutics Inc (NASDAQ:ZVSA) dipped 36.5% to $4.76.
• Netcapital Inc. (NASDAQ:NCPL) shares dipped 33.3% to $1.47 after the company announced pricing of a public offering.
• OpGen, Inc. (NASDAQ:OPGN) fell 29.8% to $0.1621. OpGen shares jumped around 85% on Tuesday after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
• Puhui Wealth Investment Management Co., Ltd. (NASDAQ:PHCF) fell 25.7% to $2.95.
• Kaspien Holdings Inc. (NASDAQ:KSPN) fell 24.2% to $0.7490 after the company reported a wider Q3 loss.
• Versus Systems Inc. (NASDAQ:VS) declined 23.1% to $0.5998.
• SeqLL Inc. (NASDAQ:SQL) dropped 21.7% to $0.3789.
• Vincerx Pharma, Inc. (NASDAQ:VINC) declined 21.7% to $0.83.
• Avadel Pharmaceuticals plc (NASDAQ:AVDL) fell 20.9% to $6.52.
• Getaround, Inc. (NYSE:GETR) fell 20.4% to $1.09.
• Bit Brother Limited (NASDAQ:BTB) dropped 20% to $0.4238 after the company announced a 1-for-15 reverse share split.
• Oriental Culture Holding LTD (NASDAQ:OCG) declined 18.8% to $0.71.
• Yumanity Therapeutics, Inc. (NASDAQ:YMTX) fell 16.8% to $1.6886. Yumanity Therapeutics recently declared a special dividend in connection with the proposed asset sale to Janssen and merger with Kineta.
• Baudax Bio, Inc. (NASDAQ:BXRX) fell 16.6% to $2.5925.
• Summit Therapeutics Inc. (NASDAQ:SMMT) fell 16.4% to $3.2691.
• Bright Health Group, Inc. (NYSE:BHG) dropped 16% to $0.6137. Goldman Sachs, on Tuesday, downgraded Bright Health from Neutral to Sell.
• Arqit Quantum Inc. (NASDAQ:ARQQ) fell 14.7% to $5.33 after the company reported FY22 results and filed for a mixed shelf of up to $100 million..
• Charter Communications, Inc. (NASDAQ:CHTR) fell 13.3% to $340.65 after it communicated an increase in 2023 capital expenditures at its analyst day held on Tuesday.
• Rubicon Technology, Inc. (NASDAQ:RBCN) shares fell 13.1% to $1.5814. Rubicon Technology announced voluntary delisting from the Nasdaq.
• Nexalin Technology, Inc. (NASDAQ:NXL) fell 11.1% to $1.7250.
• Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) dropped 11% to $12.32.
• LAVA Therapeutics N.V. (NASDAQ:LVTX) fell 9.4% to $4.20. LAVA Therapeutics announced updated data from the Phase 1/2a clinical trial of LAVA-051 at the 64th American Society of Hematology Annual Meeting and Exposition.
• Panbela Therapeutics, Inc. (NASDAQ:PBLA) fell 7.1% to $0.1327 after gaining around 53% on Tuesday. Panbela Therapeutics, last month, posted a Q3 loss of $0.21 per share.

Also check this out Bitcoin Tops $18,000; GMX, Dogecoin Among Top Losers.